Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company is conducting a Phase 3, ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Eli Lilly and Company (NYSE: LLY) is one of the best stocks to invest in for long-term growth. Eli Lilly and Company ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Eli Lilly is investing up to $4 billion in the Bristol project and Wisconsin plans to provide up to $100 million in ...